Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 158 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Targeting Inflammation Emerges as a Strategy for Treating Cancer August 19, 2022 Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... March 21, 2022 A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort... September 21, 2023 Working Outdoors in the Sunshine May Lower Your Risk of Breast... February 18, 2021 Load more HOT NEWS GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate...
